ATE402956T1 - Neue, mhc klasse ii assoziierte peptide - Google Patents
Neue, mhc klasse ii assoziierte peptideInfo
- Publication number
- ATE402956T1 ATE402956T1 AT03748078T AT03748078T ATE402956T1 AT E402956 T1 ATE402956 T1 AT E402956T1 AT 03748078 T AT03748078 T AT 03748078T AT 03748078 T AT03748078 T AT 03748078T AT E402956 T1 ATE402956 T1 AT E402956T1
- Authority
- AT
- Austria
- Prior art keywords
- mhc class
- antigenic peptides
- associated peptides
- tumors
- present
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 102100021238 Dynamin-2 Human genes 0.000 abstract 1
- 108010056472 Eukaryotic Initiation Factor-4A Proteins 0.000 abstract 1
- 102000006354 HLA-DR Antigens Human genes 0.000 abstract 1
- 108010058597 HLA-DR Antigens Proteins 0.000 abstract 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 102000051089 Melanotransferrin Human genes 0.000 abstract 1
- 108700038051 Melanotransferrin Proteins 0.000 abstract 1
- 102000013127 Vimentin Human genes 0.000 abstract 1
- 108010065472 Vimentin Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 210000005048 vimentin Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02022224 | 2002-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402956T1 true ATE402956T1 (de) | 2008-08-15 |
Family
ID=32049974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03748078T ATE402956T1 (de) | 2002-10-02 | 2003-09-24 | Neue, mhc klasse ii assoziierte peptide |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050202009A1 (de) |
| EP (1) | EP1549673B1 (de) |
| JP (1) | JP2006518982A (de) |
| CN (3) | CN101185754A (de) |
| AT (1) | ATE402956T1 (de) |
| AU (1) | AU2003267401A1 (de) |
| CA (1) | CA2498854A1 (de) |
| DE (1) | DE60322559D1 (de) |
| WO (1) | WO2004031230A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007097828A2 (en) * | 2006-01-06 | 2007-08-30 | The Johns Hopkins University | Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay |
| JP5555952B2 (ja) * | 2007-08-20 | 2014-07-23 | オンコセラピー・サイエンス株式会社 | Ｆｏｘｍ１ペプチドおよびこれを含む薬剤 |
| JP5147852B2 (ja) | 2007-10-18 | 2013-02-20 | 株式会社メディカル・プロテオスコープ | 手術後の予後を推定する方法及び診断キット |
| US9279011B2 (en) * | 2009-05-05 | 2016-03-08 | The Johns Hopkins University | Phosphopeptides as melanoma vaccines |
| CA2768398C (en) * | 2009-07-24 | 2020-01-07 | Rhode Island Hospital | Dendritic cell vaccines for asparaginyl-.beta.-hydroxylase expressing tumors |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| CA2955456A1 (en) * | 2014-07-17 | 2016-01-21 | Brian J. Czerniecki | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| US20170168055A1 (en) * | 2015-12-11 | 2017-06-15 | Expression Pathology, Inc. | SRM/MRM Assays |
| CN109069604A (zh) * | 2016-02-22 | 2018-12-21 | 欧申赛德生物技术公司 | 新抗原组合物及其在免疫肿瘤治疗中的使用方法 |
| AU2018251839B2 (en) | 2017-04-10 | 2022-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| CA3104387A1 (en) * | 2018-06-19 | 2019-12-26 | Fondazione Telethon | Production of engineered dendritic cells and uses thereof |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| WO2021006328A1 (en) | 2019-07-10 | 2021-01-14 | Chugai Seiyaku Kabushiki Kaisha | Claudin-6 binding molecules and uses thereof |
| GB202006760D0 (en) * | 2020-05-07 | 2020-06-24 | Univ Helsinki | Bioinformatics |
| CN112618712A (zh) * | 2021-01-21 | 2021-04-09 | 武汉轻工大学 | 一种含波形蛋白的佐剂及应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
-
2003
- 2003-09-24 JP JP2004540683A patent/JP2006518982A/ja active Pending
- 2003-09-24 EP EP03748078A patent/EP1549673B1/de not_active Expired - Lifetime
- 2003-09-24 WO PCT/EP2003/010602 patent/WO2004031230A2/en not_active Ceased
- 2003-09-24 AU AU2003267401A patent/AU2003267401A1/en not_active Abandoned
- 2003-09-24 CN CNA2007101422941A patent/CN101185754A/zh active Pending
- 2003-09-24 CA CA002498854A patent/CA2498854A1/en not_active Abandoned
- 2003-09-24 CN CNB03823680XA patent/CN100347191C/zh not_active Expired - Fee Related
- 2003-09-24 AT AT03748078T patent/ATE402956T1/de not_active IP Right Cessation
- 2003-09-24 DE DE60322559T patent/DE60322559D1/de not_active Expired - Fee Related
- 2003-09-24 CN CNA2007101422956A patent/CN101260154A/zh active Pending
- 2003-10-01 US US10/676,675 patent/US20050202009A1/en not_active Abandoned
-
2006
- 2006-11-20 US US11/602,144 patent/US20070073042A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004031230A3 (en) | 2005-01-13 |
| CN101185754A (zh) | 2008-05-28 |
| CN100347191C (zh) | 2007-11-07 |
| CN101260154A (zh) | 2008-09-10 |
| DE60322559D1 (de) | 2008-09-11 |
| CN1688602A (zh) | 2005-10-26 |
| JP2006518982A (ja) | 2006-08-24 |
| US20050202009A1 (en) | 2005-09-15 |
| CA2498854A1 (en) | 2004-04-15 |
| EP1549673A2 (de) | 2005-07-06 |
| WO2004031230A2 (en) | 2004-04-15 |
| US20070073042A1 (en) | 2007-03-29 |
| AU2003267401A1 (en) | 2004-04-23 |
| EP1549673B1 (de) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE402956T1 (de) | Neue, mhc klasse ii assoziierte peptide | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| CY1107042T1 (el) | Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων | |
| PT2092938E (pt) | Péptidos derivados de survivina e a sua utilização | |
| NZ516381A (en) | Lung tumor proteins in the therapy and diagnosis of lung cancer | |
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| CY1110862T1 (el) | Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| EP2193804A3 (de) | Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene | |
| EA200100395A1 (ru) | Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием | |
| ATE239035T1 (de) | Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen | |
| ATE475710T1 (de) | Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs | |
| WO2023192820A3 (en) | Tumor-associated antigens in brain tumors | |
| DE60120507D1 (de) | Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1 | |
| ATE308565T1 (de) | Immunogene alk (anaplastic lymphoma kinase) peptide | |
| CY1108790T1 (el) | Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου | |
| ATE243760T1 (de) | Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen | |
| ATE480250T1 (de) | Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion | |
| EA202192991A1 (ru) | Новые раковые антигены и сопутствующие способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |